Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicinal composition containing zidovudine, valproic acid or its salt

A technology of zidovudine and valproic acid, which can be used in medical preparations containing active ingredients, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as lipodystrophy, infection, and high price.

Inactive Publication Date: 2006-04-26
北京明新高科技发展有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This kind of virus that stops replicating and has no activity "hides" in the cells, and antiviral drugs cannot kill them. Once the patient stops using antiviral drugs, these viruses will "wake up" again and enter the state of replication, causing new In addition to being expensive, "cocktail therapy" also has some disadvantages that cannot be ignored
One is the side effects. This therapy often causes gastrointestinal reactions, such as nausea, vomiting, diarrhea, etc.; it also inhibits the hematopoietic function of the bone marrow, causing severe anemia; in addition, it can also cause lipodystrophy, such as buffalo back, spider man and central obesity etc.; the second is drug resistance. After 3 or 4 months of medication, the effect will not be good, and the drug must be selected again.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing zidovudine, valproic acid or its salt
  • Medicinal composition containing zidovudine, valproic acid or its salt

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] 2. Preparation method

[0043] Zidovudine, valproic acid, lactose, microcrystalline cellulose and CMS-Na of above-mentioned prescription quantity are crossed 100 mesh sieves, mix homogeneously, cross 60 mesh sieves, add binding agent PVP (1% aqueous solution) and Tween -80 (1% anhydrous ethanol) appropriate amount of soft material, granulated with a 20-mesh sieve, dried at 80°C, granulated with a 20-mesh sieve, added magnesium stearate as a lubricant, mixed evenly, and pressed into tablets, each tablet weighed 0.75 g.

Embodiment 2

[0046] 2. Preparation method

[0047] Pass the zidovudine, sodium valproate, pregelatinized starch and cCMS-Na of the above prescription amount through a 100 mesh sieve, mix well, pass through a 60 mesh sieve, add an appropriate amount of binder 95% ethanol and 2% Tween solution Make soft material, granulate with 20-mesh sieve, dry at 50-60°C, granulate with 20-mesh sieve, add magnesium stearate as lubricant, mix well, press into tablets, each tablet weighs 0.80g.

Embodiment 3

[0050] 2. Preparation method

[0051] Zidovudine, valproic acid, pregelatinized starch, lactose, CMS-Na of above-mentioned recipe quantity are crossed 100 mesh sieves, mix homogeneously, cross 60 mesh sieves, add binding agent 95% ethanol and 2% Tween ( Appropriate amount of 1% absolute ethanol) solution to make soft material, granulate with 20 mesh sieve, dry at 50-60°C, granulate with 20 mesh sieve, add stearic acid and micropowder silica gel as lubricant, mix well, press into tablets, each piece Weighs 0.69g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a therapeutic combination containing Azidothimidine and dipropylacetic acid or its salts, wherein the formulation of the medicinal composition comprises (by weight percentage) Azidothimidine 0.1-95%, dipropylacetic acid or its salts 1.0-95%, and medicinal auxiliary material 4-98.9%. Each unit of the dosage preferably comprises Azidothimidine 10-600mg, dipropylacetic acid or its salts 50-500mg, and pharmaceutically acceptable auxiliary materials amounting to 15-40% of the total weight of the unit dosage. The combination can be used for the treatment of human immunodeficiency virus (HIV) infection.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition containing active ingredients zidovudine and valproic acid or a salt thereof for treating immunodeficiency syndrome caused by human immunodeficiency virus infection. Background technique: [0002] Aquired immunodeficiency syndrome (AIDS), commonly known as AIDS, caused by human immunodeficiency virus (human immunodeficiency virus, HIV) infection, is currently widespread worldwide and has become a major public health and social problem that has attracted worldwide attention. Now it is generally believed that HIV is the cause of AIDS and AIDS-related syndrome (AIDS-related complex, ARC). Not only is HIV the leading cause of AIDS, but HIV infection alone often causes over time such profound immunodeficiency that the patient dies. Due to public attention, HIV has also become one of the most well-studied viruses in history. Despite scientists' efforts, there is still no effective or even satisfactory ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7072A61K31/19A61P31/18
Inventor 王秀英张春颖张大德王秀云肖佳普
Owner 北京明新高科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com